

**NICE TA 244: Roflumilast for the management of severe Chronic Obstructive  
Pulmonary Disease (COPD)**

|            |   |
|------------|---|
| <b>1</b>   | <b>Name of Commissioning Team</b><br><br>Long Term Conditions Commissioning Team  |
| <b>2</b>   | <b>Summary of NICE TA 244</b><br><br>NICE has recommended the use of roflumilast only in the context of research as part of a clinical trial.                                   |
| <b>3</b>   | <b>Number of people in Northern Ireland expected to take up service/therapy (new cases per year)</b><br><br>Estimated 40 people in Northern Ireland are prescribed this regime. |
| <b>4</b>   | <b>Outcomes</b>   |
| <b>4.1</b> | <b>Additional life expectancy gain / progress improvement</b><br><br>N/A  |
| <b>4.2</b> | <b>Reduction in morbidity</b><br><br>N/A  |
| <b>4.3</b> | <b>Cost per patient per annum</b><br><br>N/A  |
| <b>4.4</b> | <b>In year cost per patient per annum (for new and prevalent cases)</b><br><br>N/A  |
| <b>4.5</b> | <b>Any cost savings and how these will be secured</b><br><br>N/A  |
| <b>4.6</b> | <b>Recurrent overall cost</b><br><br>N/A  |
| <b>4.7</b> | <b>Cost per QALY</b>  |

|            |   |
|------------|---|
|            | N/A   |
| <b>4.8</b> | <b>Other treatments available for this condition</b><br><br>N/A   |
| <b>4.9</b> | <b>Readiness to implement</b><br><br>N/A  |
| <b>5</b>   | <b>Legislative / policy caveats</b><br><br>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.            |
| <b>6</b>   | <b>What will Commissioning Team do to secure funding for the implementation of this TA including any proposals for disinvestment</b><br><br>GPs have been contacted about the need to review and discontinue this drug. This drug is normally initiated by secondary care and there may be some referral back to secondary care (if not currently under secondary care review) by GPs.<br><br>Respiratory physicians in secondary care will be written to advise of this guidance and the need to discontinue if appropriate. |
| <b>7</b>   | <b>Commissioning arrangements</b><br><br>N/A  |
| <b>8</b>   | <b>Monitoring arrangements</b><br><br>Drug prescribing will continue to be monitored to see that Roflumilast is being discontinued as appropriate and is not being started anew in any patient.   |